Immunological progress remains a widely used form of HIV/ART monitoring, and efavirenz a preferred first line antiretroviral drug. The host for HIV may vary basing on CD4 cell type or values, genetic differences, and co-infections. CD4 cell values vary among HIV seronegative populations and among HIV patients starting ART. Variations in pharmacokinetics and pharmacogenetics of efavirenz are widely documented. This book reports on the role of variability in relevant baseline immunological characteristics among HIV negative ...
Read More
Immunological progress remains a widely used form of HIV/ART monitoring, and efavirenz a preferred first line antiretroviral drug. The host for HIV may vary basing on CD4 cell type or values, genetic differences, and co-infections. CD4 cell values vary among HIV seronegative populations and among HIV patients starting ART. Variations in pharmacokinetics and pharmacogenetics of efavirenz are widely documented. This book reports on the role of variability in relevant baseline immunological characteristics among HIV negative and positive populations and how variations in the pharmacokinetics and pharmacogenetics of efavirenz can affect HIV/ART response.
Read Less
Add this copy of Host Variabilities Influencing HIV/ART Outcomes to cart. $55.56, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2013 by Scholars' Press.
Add this copy of Host Variabilities Influencing Hivart Outcomes the Role to cart. $77.30, new condition, Sold by Paperbackshop rated 5.0 out of 5 stars, ships from Bensenville, IL, UNITED STATES, published 2013 by Scholars' Press.
Add this copy of Host Variabilities Influencing Hiv/Art Outcomes: the to cart. $99.92, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2013 by Scholars' Press.